Filtered By:
Therapy: Immunotherapy
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2387 results found since Jan 2013.
Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
CONCLUSION: This review summarises important predictive ncRNA biomarkers that were reported in cancer patients treated with different immunotherapeutic modalities, including monoclonal antibodies, small molecule inhibitors, cancer vaccines and CAR-T cells. In addition, a concise discussion on forthcoming perspectives is provided, outlining technical approaches for the optimal utilisation of immunomodulatory ncRNA biomarkers as predictive tools and therapeutic targets.PMID:37735815 | DOI:10.1002/ctm2.1425
Source: Clinical Lung Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Murad Alahdal Eyad Elkord Source Type: research
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
CONCLUSION: In HLA-A2 positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to chemotherapy. Further evaluation in this population is warranted.PMID:37704166 | DOI:10.1016/j.annonc.2023.07.006
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: B Besse E Felip R Garcia Campelo M Cobo C Mascaux A Madroszyk F Cappuzzo W Hilgers G Romano F Denis S Viteri D Debieuvre D Galetta E Baldini None M Razaq G Robinet M Maio A Delmonte B Roch P Masson W Schuette A Zer J Remon D Costantini B Vasseur R Dziadzi Source Type: research
Recurrent Glioblastoma: A Review of the Treatment Options
Cancers (Basel). 2023 Aug 26;15(17):4279. doi: 10.3390/cancers15174279.ABSTRACTGlioblastoma is a disease with a poor prognosis. Multiple efforts have been made to improve the long-term outcome, but the 5-year survival rate is still 5-10%. Recurrence of the disease is the usual way of progression. In this situation, there is no standard treatment. Different treatment options can be considered. Among them would be reoperation or reirradiation. There are different studies that have assessed the impact on survival and the selection of patients who may benefit most from these strategies. Chemotherapy treatments have also been c...
Source: Hand Surgery - September 9, 2023 Category: Surgery Authors: Maria Angeles Vaz-Salgado Mar ía Villamayor V íctor Albarrán V íctor Alía Pilar Sotoca Jes ús Chamorro Diana Rosero Ana M Barrill Mercedes Mart ín Eva Fernandez Jos é Antonio Gutierrez Luis Mariano Rojas-Medina Luis Ley Source Type: research
Stimuli-Responsive Hydrogel Microcapsules Harnessing the COVID-19 Immune Response for Cancer Therapeutics
We present the development of stimuli-responsive microcapsules, loaded with a viral immunogenetic agent, harnessing the immune response against the Coronavirus Disease 2019, COVID-19, to selectively attack liver cancer cells (hepatoma) or recognize breast cancer or hepatoma, by expression of green fluorescence protein, GFP. The pH-responsive microcapsules, modified with DNA-tetrahedra nanostructures, increased hepatoma permeation by 50%. Incorporation of a GFP-encoding lentivirus vector inside the tumor-targeting pH-stimulated miRNA-triggered and Alpha-fetoprotein-dictated microcapsules enables the demonstration of neoplas...
Source: Angewandte Chemie - September 7, 2023 Category: Chemistry Authors: Amit Fischer Avner Ehrlich Yevgeni Plotkin Yu Ouyang Klil Asulin Ioannidis Konstantinos Chunhai Fan Yaakov Nahmias Itamar Willner Source Type: research
Developments in targeted therapy & amp; immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review
CONCLUSIONS: This review encompasses the latest updates in targeted therapy and immunotherapy in lung cancer management and discusses the future direction in the field.PMID:37675321 | PMC:PMC10477626 | DOI:10.21037/atm-22-4444
Source: Cancer Control - September 7, 2023 Category: Cancer & Oncology Authors: Molly S C Li Kevin K S Mok Tony S K Mok Source Type: research
mRNA vaccine in gastrointestinal tumors: Immunomodulatory effects and immunotherapy
Biomed Pharmacother. 2023 Sep 1;166:115361. doi: 10.1016/j.biopha.2023.115361. Online ahead of print.ABSTRACTGastrointestinal tumors remain a significant healthcare burden worldwide, necessitating the development of innovative therapeutic strategies. mRNA vaccines have emerged as a promising approach in cancer immunotherapy, harnessing the immune system's potential to recognize and eliminate tumor cells. mRNA vaccines offer several advantages, including their ability to elicit both innate and adaptive immune responses, ease of production, and adaptability to different tumor types. In the context of gastrointestinal tumors,...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 3, 2023 Category: Drugs & Pharmacology Authors: Ao Zhang Qingming Ji Xia Sheng Hui Wu Source Type: research
Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development
Environ Res. 2023 Aug 31:117027. doi: 10.1016/j.envres.2023.117027. Online ahead of print.ABSTRACTThe latest advancements in oncology involves the creation of multifunctional nanostructures. The integration of nanoparticles into the realm of cancer therapy has brought about a transformative shift, revolutionizing the approach to addressing existing challenges and limitations in tumor elimination. This is particularly crucial in combating the emergence of resistance, which has significantly undermined the effectiveness of treatments like chemotherapy and radiotherapy. GO stands as a carbon-derived nanoparticle that is incre...
Source: Environmental Research - September 2, 2023 Category: Environmental Health Authors: Mohammad Saleh Sadeghi Faezeh Hosseini Sangrizeh Negar Jahani Mahdi Sadegh Abedin Soheila Chaleshgari Alireza Khodaei Ardakan Reza Baeelashaki Golnaz Ranjbarpazuki Parham Rahmanian Mohammad Arad Zandieh Noushin Nabavi Amir Reza Aref Shokooh Salimimoghadam Source Type: research
CAR T cells ignite antitumor immunity
Trends Immunol. 2023 Aug 29:S1471-4906(23)00156-4. doi: 10.1016/j.it.2023.08.002. Online ahead of print.ABSTRACTBroadening immune responses through antigen spreading remains the 'Holy Grail' of cancer immunotherapy. A study by Ma and colleagues reveals that vaccine boosting of chimeric antigen receptor (CAR)-T cells in mice promotes endogenous immunity and elicits antigen spread to eliminate antigenically heterogenous solid tumors through a mechanism crucially dependent on interferon (IFN)γ.PMID:37652814 | DOI:10.1016/j.it.2023.08.002
Source: Trends in Immunology - August 31, 2023 Category: Allergy & Immunology Authors: Darya Alizadeh Christine E Brown Source Type: research
